ComGenex, Inc. has changed its name to AMRI Hungary. The
name change results from the acquisition of ComGenex by U.S.-based
Albany Molecular Research, Inc. (NASDAQ:AMRI) in February 2006.
Located in Budapest, AMRI Hungary has become the European center
for AMRI, a global pharmaceutical research, development and
manufacturing company with a full range of integrated services--from
the identification of hit compounds, to powerful medicinal chemistry
SAR optimization, to the production of pharmaceutical ingredients for
clinical and commercial use.
Through the acquisition, clients of AMRI Hungary now have access
to the comprehensive services provided by AMRI. Moreover, the
integration of AMRI's research sites in the United States, Europe, and
Asia provides the company's customers with a flexible range of
services, capabilities and cost structures.
As part of the AMRI brand, AMRI Hungary integrates innovative,
early stage drug discovery technologies, including proprietary methods
in the area of library synthesis, compound collections and lead
discovery. In the future, AMRI Hungary plans to expand its
capabilities in medicinal chemistry and SAR development.
The first tangible advantage of AMRI Hungary's addition to the
global AMRI network is the availability of AMRI Hungary's new,
expanded and integrated lead-seeking library--which is more diverse
than before and includes new core structures.
Albany Molecular Research, Inc. is a global drug discovery company
that provides chemistry services to pharmaceutical and biotechnology
companies and conducts its own proprietary R&D programs. For more
information, visit www.albmolecular.com.
Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that involve risks and
uncertainties. These statements may be identified by forward-looking
words such as "may," "could," "should," "would," "will," "intend,"
"expect," "anticipate," "believe" and "continue" or similar words and
include, without limitation, statements regarding the company's
proposed expansion in Budapest. Readers should not place undue
reliance on our forward-looking statements. The company's actual
results may differ materially from such forward-looking statements as
a result of numerous factors, some of which the company may not be
able to predict and may not be within the company's control. Factors
that could cause such differences include, but are not limited to the
company's ability to attract and retain experienced scientists, trends
in pharmaceutical and biotechnology companies outsourcing of chemical
research and development, the company's ability to enforce its
intellectual property and technology rights, the risks posed by
international operations to the company, and the company's ability to
effectively manage its growth as well as those factors discussed in
the company's Annual Report on Form 10-K for the year ended December
31, 2005 as filed with the Securities and Exchange Commission on March
16, 2006 and the company's other SEC filings. The company does not
undertake any duty to and does not intend to update any
forward-looking statements contained in this press release after the
date of this press release.
